Hubbry Logo
search
logo
Cathine avatar
Cathine
Cathine
current hub
2172820

Cathine

logo
Community Hub0 Subscribers
Read side by side
Cathine
View on Wikipedia
from Wikipedia
Cathine
Clinical data
Other names
  • (+)-Norpseudoephedrine
  • Cathine
  • (1S,2S)-β-Hydroxyamphetamine
Routes of
administration		Oral
Drug class
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life1.8–8.6 hours[2]
Identifiers
  • (1S,2S)-2-amino-1-phenylpropan-1-ol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.007.050 Edit this at Wikidata
Chemical and physical data
FormulaC9H13NO
Molar mass151.209 g·mol−1
3D model (JSmol)
Solubility in water20 mg/mL (20 °C)
  • O[C@@H](c1ccccc1)[C@@H](N)C
  • InChI=1S/C9H13NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7,9,11H,10H2,1H3/t7-,9+/m0/s1 checkY
  • Key:DLNKOYKMWOXYQA-IONNQARKSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Cathine, also known as D-norpseudoephedrine or as (+)-norpseudoephedrine, is a psychoactive drug of the phenethylamine and amphetamine groups which acts as a stimulant. Along with cathinone, it is found naturally in Catha edulis (khat), and contributes to the overall effects of the plant.[3] Cathine has approximately 7 to 10% of the potency of amphetamine.[3]

Pharmacology

[edit]

Like amphetamines, cathinone and ephedrine, cathine acts as a norepinephrine releasing agent (NRA).[3] It also acts as a dopamine releasing agent (DRA).[3][4]

Monoamine release by cathine and related agents (EC50Tooltip half maximal effective concentration, nM)
Compound NETooltip Norepinephrine DATooltip Dopamine 5-HTTooltip Serotonin Ref
Dextroamphetamine (S(+)-amphetamine) 6.6–7.2 5.8–24.8 698–1,765 [5][6]
S(–)-Cathinone 12.4 18.5 2,366 [7]
Ephedrine ((–)-ephedrine) 43.1–72.4 236–1,350 >10,000 [5]
(+)-Ephedrine 218 2,104 >10,000 [5][7]
Dextromethamphetamine (S(+)-methamphetamine) 12.3–13.8 8.5–24.5 736–1,292 [5][8]
Levomethamphetamine (R(–)-methamphetamine) 28.5 416 4,640 [5]
(+)-Phenylpropanolamine ((+)-norephedrine) 42.1 302 >10,000 [7]
(–)-Phenylpropanolamine ((–)-norephedrine) 137 1,371 >10,000 [7]
Cathine ((+)-norpseudoephedrine) 15.0 68.3 >10,000 [7]
(–)-Norpseudoephedrine 30.1 294 >10,000 [7]
(–)-Pseudoephedrine 4,092 9,125 >10,000 [7]
Pseudoephedrine ((+)-pseudoephedrine) 224 1,988 >10,000 [7]
Notes: The smaller the value, the more strongly the drug releases the neurotransmitter. The assays were done in rat brain synaptosomes and human potencies may be different. See also Monoamine releasing agent § Activity profiles for a larger table with more compounds. Refs:[9][10]

Chemistry

[edit]

Cathine is one of the four stereoisomers of phenylpropanolamine (PPA).

Regulation

[edit]

The World Anti-Doping Agency's list of prohibited substances (used for the Olympic Games among other athletic events) bans cathine in concentrations of over 5 micrograms per milliliter in urine. Cathine is a Schedule III drug under the Convention on Psychotropic Substances.[11] In the United States, it is classified as a Schedule IV controlled substance.[12]

In Australia, Cathine is officially a schedule 4 drug prescription only, but is not available or approved for any medical use.

Cathine is found in the shrub khat (Catha edulis).

In Hong Kong, cathine is regulated under Schedule 1 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. Unlawful possession is punishable by severe fines and imprisonment.

Pregnancy

[edit]

Ephedra, found in many Ephedraceae species, is a Chinese and Western herb that contains, among other amphetamines, D-norpseudoephedrine. In the National Birth Defects Prevention Study, which included 18,438 women from 10 states from 1999 to 2003, 1.3% of women reported using ephedra during pregnancy. During the trial, five cases of anencephaly were born to women who used ephedra, however there was no statistically significant association to women not using ephedra (odds ratio 2.8, confidence interval 1.0–7.3).[13]

A small study of 642 participants in Yemen found that among pregnant women who chewed khat (containing D-norpseudoephedrine) there was no increased risk of stillbirth or congenital malformations.[14] Among lactating women who chew khat, D-norpseudoephedrine is found in breastmilk.[15]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Cathine

View on Grokipedia
from Grokipedia
Cathine, chemically (1S,2S)-2-amino-1-phenylpropan-1-one or norpseudoephedrine, is a naturally occurring monoamine alkaloid and central nervous system stimulant found in the leaves of the khat shrub (Catha edulis).[1][2] It functions as a sympathomimetic agent, primarily by promoting the release of norepinephrine and, to a lesser extent, dopamine in the brain, resulting in mild amphetamine-like effects including heightened alertness, mild euphoria, and appetite suppression.[3][4] As a secondary alkaloid derived from the metabolism of cathinone—the more potent primary stimulant in fresh khat—cathine persists in dried leaves, sustaining psychoactive activity over longer periods when khat is stored or chewed in non-fresh forms.[3][5] While traditionally chewed for sociability and fatigue reduction in East African and Arabian cultures, cathine's pharmacological profile has led to its classification as a controlled substance in many countries, including Schedule IV under the U.S. Controlled Substances Act, due to potential for abuse, dependence, and adverse effects such as insomnia, anxiety, and cardiovascular strain observed in chronic users.[1][3] Empirical studies indicate lower potency compared to synthetic amphetamines, with toxicity risks amplified by poly-substance use or high-dose consumption rather than inherent lethality.[4][3]

History and Natural Occurrence

Discovery and Isolation

Cathine, also known as (+)-norpseudoephedrine, was first isolated in 1930 from the leaves of Catha edulis (khat) by German pharmacologist Otto Wolfes, who extracted the alkaloid from dried plant material using solvent-based methods typical of early 20th-century phytochemical analysis.[6] [5] Wolfes identified cathine as the predominant alkaloid accounting for the stimulant properties attributed to khat at the time, particularly in dried preparations where fresher components had degraded.[7] Its structure was elucidated as d-norpseudoephedrine, a phenethylamine lacking the N-methyl group found in pseudoephedrine, through comparative chemical assays and optical rotation measurements confirming its levorotatory nature relative to known ephedrine derivatives.[5] Independent isolations followed, including by Alles and colleagues in 1961, who employed chromatographic techniques to purify and verify cathine from khat extracts, reinforcing its role as a mild central stimulant with amphetamine-like properties but lower potency.[6] These efforts relied on acid-base extraction from macerated leaves, followed by crystallization and spectroscopic confirmation, though early methods were limited by the instability of related khat alkaloids.[8] By the 1970s, advanced isolation of cathinone from fresh khat in 1975 revealed cathine as its primary degradation product, formed via reduction of the ketone group in cathinone during post-harvest drying or storage, explaining the diminished psychoactivity of aged leaves.[6] This causal link was established through controlled degradation experiments and comparative alkaloid profiling, shifting understanding of cathine's secondary role in khat's overall pharmacology.[9]

Traditional Use in Khat Chewing Cultures

Khat chewing, the primary traditional method of cathine consumption, originated in the Harar region of eastern Ethiopia and has been practiced for nearly 800 years, subsequently spreading to neighboring Somalia and across the Red Sea to Yemen by the 14th century.[10][11] In these regions, fresh khat leaves (Catha edulis) are harvested and chewed communally during extended social sessions, often in dedicated spaces known as mafrishes or khat houses, where participants form bundles of tender twigs and leaves into cheek-filling wads retained for hours to extract alkaloids including cathine and cathinone.[12][13] This practice serves laborers, students, and social groups seeking enhanced alertness, sociability, and endurance for prolonged work or discussions, with cathine contributing to mild stimulant effects alongside appetite suppression that aligns with intermittent fasting-like patterns in some users.[14][15] In Yemen, khat sessions typically occur in the afternoon, integrating into daily routines as a cultural staple, while in Ethiopia's Harar and Somali communities, chewing fosters communal bonding and is tied to Islamic scholarly traditions despite periodic religious debates.[13] Economic significance is pronounced, with khat cultivation supporting livelihoods in producing areas; for instance, it constitutes a major cash crop in Yemen, where daily consumption patterns drive substantial trade volumes.[16] Globally, an estimated 10 million people engage in khat chewing, predominantly daily users in Ethiopia, Yemen, and Somalia, reflecting entrenched cultural norms rather than isolated pharmacological pursuit of cathine.[17][18] Empirical patterns indicate higher prevalence among adult males, with Yemeni men reporting rates of 70-90%, underscoring khat's role in sustaining productivity in agrarian and pastoral economies amid limited alternatives for stimulation.[19]

Chemistry

Chemical Structure and Properties

Cathine, systematically named (1S,2S)-2-amino-1-phenylpropan-1-ol and also known as D-norpseudoephedrine, possesses the molecular formula C₉H₁₃NO and a molar mass of 151.21 g/mol.[1] [2] Its structure consists of a phenethylamine backbone with a β-hydroxy group and a methyl substituent on the alpha carbon, distinguishing it as a phenylpropanolamine derivative closely related to ephedrine but lacking the N-methyl group on the amine.[1] [2] This configuration places cathine within the class of amphetamine analogs, specifically as a substituted phenethylamine.[1] The compound exhibits the (1S,2S)-stereochemistry in its naturally occurring form, corresponding to the dextrorotatory enantiomer.[1] [20] Physical properties include a melting point of 77.5–78 °C and water solubility of 20 g/L at 25 °C, with a calculated logP value of 0.83 indicating moderate lipophilicity.[2] [1] In pure form, cathine manifests as a white crystalline solid.[2] Natural cathine extracted from Catha edulis is predominantly the (1S,2S)-isomer, while synthetic variants may incorporate racemic mixtures or other stereoisomers, potentially introducing impurities such as diastereomers or residual solvents depending on the production process.[1]

Biosynthesis and Degradation in Plants

Cathine, also known as norpseudoephedrine, is biosynthesized in the leaves of Catha edulis primarily as a secondary metabolite derived from L-phenylalanine. The pathway begins with the decarboxylation of L-phenylalanine to phenylpyruvic acid, followed by oxidation to 1-phenylpropane-1,2-dione, and transamination to form (S)-cathinone, which serves as the direct precursor to cathine.[21] Cathinone undergoes enzymatic reduction, likely via reductases, to yield (+)-cathine, with this process occurring alongside the formation of related alkaloids like norephedrine.[22] In actively growing plant tissues, particularly young leaves, cathinone predominates as the primary alkaloid, while cathine accumulates to lesser extents, reflecting the plant's prioritization of cathinone for potential defensive or signaling roles.[23] Post-harvest degradation of cathinone to cathine occurs rapidly due to endogenous enzymes in the detached leaves, converting the β-keto group of cathinone to a hydroxyl via reduction, thereby diminishing the plant material's potency as cathinone levels decline.[24] This bioconversion is exacerbated by drying or storage conditions, where cathinone stability decreases within 48 hours, leading to elevated cathine concentrations over time.[3] Fresh C. edulis leaves typically contain cathine at 0.172–0.192% by dry weight, with cathinone at 0.115–0.158%, whereas subsequent drying increases cathine to 0.184–0.198% as cathinone degrades.[25] These shifts explain the preference for fresh khat in traditional use, as the enzymatic degradation reduces psychoactive cathinone while cathine, being less potent, accumulates.[26] Factors such as temperature, humidity, and post-harvest handling influence the rate, with refrigeration slowing but not halting the process.[27] Overall, cathine levels in dried khat range from 0.1% to approximately 1%, varying by cultivar, leaf age, and environmental conditions during growth.[28]

Pharmacology

Mechanism of Action

Cathine primarily acts as a monoamine releasing agent, inducing the efflux of norepinephrine from sympathetic nerve terminals and, to a lesser degree, dopamine from dopaminergic neurons, through reversal of the norepinephrine transporter (NET) and dopamine transporter (DAT).[29][30] This substrate-like interaction promotes carrier-mediated exchange, depleting presynaptic vesicular stores and elevating synaptic catecholamine levels, akin to but weaker than the actions of amphetamine.[29] Cathine exhibits modest reuptake inhibition at NET and DAT, contributing to its sympathomimetic profile, while displaying minimal affinity or activity at the serotonin transporter (SERT).[29] Its potency as a releaser ranks below that of cathinone and amphetamine, with EC50 values for norepinephrine release around 15-fold higher and dopamine release approximately 68-fold higher than potent analogs, reflecting reduced efficacy in evoking transporter reversal. At low doses, cathine preferentially activates adrenergic pathways, mimicking mild endogenous norepinephrine signaling without substantial dopaminergic dominance.[29] As a trace amine analog, cathine likely engages trace amine-associated receptor 1 (TAAR1) to modulate monoamine transporter conformation, enhancing release, though direct binding data remain limited compared to amphetamines.[31] Interactions with vesicular monoamine transporter 2 (VMAT2) facilitate cytosolic accumulation and subsequent efflux, underscoring its indirect sympathomimetic mechanism.[29]

Pharmacokinetics

Cathine is primarily absorbed through the oral mucosa during khat chewing, accounting for approximately 84% of uptake, with the remaining 16% occurring via the stomach and small intestine. This buccal absorption facilitates rapid entry into the bloodstream, with peak plasma concentrations typically achieved 2.6 ± 0.77 hours after the onset of chewing.[26][32] Cathine follows a two-compartment pharmacokinetic model, with distribution influenced by its lipophilic nature allowing penetration into tissues. The terminal elimination half-life averages 5.2 ± 3.4 hours in human volunteers, reflecting substantial interindividual variability attributable to factors such as chewing efficiency and extraction of alkaloids from leaves (approximately 90% yield).[26][32][2] Metabolism of cathine is minimal and primarily hepatic, though specific cytochrome P450 enzymes involved remain undetailed in human studies; it does not undergo significant biotransformation like its precursor cathinone. Instead, cathine is predominantly excreted unchanged in the urine, detectable within 30-50 minutes post-ingestion and persisting for several hours aligned with its half-life.[33][26]

Physiological and Psychological Effects

Acute Effects

Cathine, administered acutely, elevates heart rate in humans in a dose-dependent fashion, with mean increases ranging from 1.2 beats per minute at 16 mg to 6.2 beats per minute at 53.3 mg doses.[34] It also modestly raises blood pressure while suppressing appetite through central anorexigenic mechanisms, as evidenced by reduced food intake in rodent models following intraperitoneal doses of 10–80 mg/kg.[29][34] Additional physiological responses include heightened locomotor activity, with distances traveled increasing to approximately 148 cm per 10 minutes at 20 mg/kg in rats, alongside hyperthermia and potential sensory stimulation.[29][34] Psychologically, cathine promotes alertness and wakefulness, shifting rodents from slow-wave sleep to active awake states for over 50 minutes post-20 mg/kg dosing, comparable to milder stimulants like caffeine at equivalent human exposures of 20–50 mg.[29] Effects manifest as increased sensory stimulation and mild euphoria in users, though less intense than amphetamine, with onset within 30–60 minutes and duration typically spanning 1–3 hours based on pharmacokinetic profiles and khat-derived intake yielding similar cathine levels.[34] Sociability may enhance transiently due to these stimulant properties, without pronounced anxiety induction at standard doses.[34]

Chronic Effects

Chronic exposure to cathine, primarily through habitual khat chewing, leads to the development of tolerance to its stimulant effects, including diminished subjective euphoria and motor stimulation, with rapid onset and dissipation observed in discriminative stimulus paradigms.[35] This tolerance is attributed to dopaminergic mechanisms similar to those in other sympathomimetics, though less pronounced than with amphetamines due to cathine's lower potency.[36] Heavy users may escalate intake to counteract this, but longitudinal data indicate partial adaptation without complete cross-tolerance to all effects, such as sustained appetite suppression contributing to persistent weight loss averaging 5-10% body mass in regular chewers over months.[37] Psychologically, chronic cathine exposure is associated with mild executive function deficits, particularly impaired inhibitory control in tasks requiring response suppression, as evidenced by neuroimaging and behavioral studies in daily khat users averaging 10-20 sessions per week.[37] These alterations persist beyond acute intoxication but are generally subtle and reversible upon abstinence, contrasting with more severe cognitive decline in methamphetamine users. Empirical reviews find no robust evidence of neurodegeneration, such as dopaminergic neuron loss, at moderate doses (equivalent to 20-50 mg cathine daily), unlike stronger amphetamines; histopathological analyses of chronic khat users show minimal striatal pathology.[38] Systemically, gastrointestinal adaptation occurs with habitual use, shifting from initial nausea to chronic hypomotility and constipation in up to 70% of long-term chewers, linked to prolonged sympathetic activation reducing peristalsis.[39] Cardiovascular adaptations include elevated baseline blood pressure (systolic increases of 10-20 mmHg in users exceeding 100 g khat daily for years), reflecting endothelial changes without acute hypertensive crises in most cases.[37] Hepatic enzyme elevations suggest mild cytotoxic stress, but progression to overt liver disease remains rare in non-polypharmacy users.[40]

Medical and Recreational Applications

Potential Therapeutic Uses

Cathine has been primarily explored as an adjunct therapy for obesity due to its sympathomimetic effects that suppress appetite and increase energy expenditure. In a 2017 randomized, double-blind, placebo-controlled dose-finding trial involving 335 obese adults (BMI ≥30 kg/m²), participants received daily doses of 8 mg, 16 mg, or 32 mg cathine or placebo alongside lifestyle interventions for 24 weeks. The 16 mg and 32 mg groups achieved mean weight losses of 6.5 kg and 6.2 kg, respectively, compared to 2.5 kg in the placebo group, with statistically significant differences (p<0.001).[34] A greater proportion of cathine-treated participants (up to 42% in the 16 mg group) experienced ≥5% body weight reduction versus 14% on placebo.[41] Preclinical studies support cathine's anti-obesity mechanism through modulation of nucleus accumbens shell neuronal activity via dopamine D1 and D2 receptors, reducing food intake without severe disruptions to reward pathways seen in stronger amphetamines.[15] However, cathine remains unapproved by regulatory bodies such as the FDA for any therapeutic use, reflecting limited large-scale, long-term clinical data beyond this single trial.[2] Exploratory interest exists in cathine's stimulant profile for conditions involving fatigue or excessive daytime sleepiness, akin to historical ephedrine applications, though empirical trials are scarce and dosages would require adjustment upward from appetite suppression levels (typically 15-30 mg).[30] Its milder potency relative to synthetic cathinone analogs positions it as potentially preferable for short-term alertness in select populations, but no randomized controlled trials substantiate efficacy for narcolepsy or depression adjunct therapy.[41] Further research is warranted to delineate causal benefits amid its Schedule IV classification under international controls.

Patterns of Recreational Use

Cathine is consumed recreationally primarily through khat (Catha edulis), a shrub native to East Africa and the Arabian Peninsula, where it constitutes a key alkaloid responsible for stimulant effects after cathinone degrades. Traditional use involves chewing fresh leaves and tender stems in social gatherings, often lasting 3 to 5 hours, with participants consuming 100 to 300 grams per session to induce mild euphoria, increased alertness, and sociability.[42] These sessions, termed "khat chewing" or "mirra," are deeply embedded in cultural practices across Yemen, Somalia, and Ethiopia, typically occurring daily or several times weekly among adult males.[3] Prevalence of khat chewing, and thus cathine exposure, remains high in origin regions, with estimates indicating 80% of Yemeni adult males and over 50% in parts of Ethiopia and Somalia engaging regularly.[43][44] Globally, 10 to 20 million individuals partake in this practice, predominantly in social contexts rather than solitary abuse.[45] Migration has propagated use to diaspora communities in Europe, the UK, and the US, where it persists among Somali, Yemeni, and Ethiopian immigrants, with lifetime prevalence reaching 63.5% in some Yemeni migrant groups in Germany, though adoption outside these enclaves is minimal.[46][47] Synthetic or isolated cathine sees sporadic non-medical application, occasionally for athletic enhancement due to its stimulant properties, despite World Anti-Doping Agency thresholds prohibiting urinary levels above 5 micrograms per milliliter.[48] Oral ingestion predominates for non-chewed forms, but polydrug combinations remain rare, with users favoring khat's natural matrix over adulterated or mixed substances. Abuse escalation is less pronounced than with cocaine, reflecting cathine's attenuated potency and culturally moderated dosing patterns.[42]

Risks, Toxicity, and Health Impacts

Cardiovascular and Neurological Risks

Cathine, the primary sympathomimetic alkaloid in Catha edulis (khat), induces acute elevations in systolic and diastolic blood pressure and heart rate through its amphetamine-like stimulation of catecholamine release and inhibition of reuptake, mimicking effects observed in experimental khat chewing sessions where mean systolic pressure rose by 14-27 mmHg and heart rate by 20-33 beats per minute within 1-3 hours.[49][50] These hemodynamic changes increase myocardial oxygen demand and can precipitate coronary vasospasm, elevating the risk of acute myocardial infarction (MI) and arrhythmias, particularly in individuals with preexisting cardiovascular vulnerabilities such as atherosclerosis or hypertension; case-control studies in Yemen reported khat chewers facing 4-5 times higher odds of MI compared to non-users, though acute events often resolve post-abstinence.[51][49] Chronic khat use, entailing daily cathine exposure via prolonged chewing, correlates with sustained hypertension in cohort analyses, including a Yemeni study of 1,605 men where regular chewers exhibited 5-10 mmHg higher systolic and diastolic pressures adjusted for age and BMI, alongside elevated risks of cardiomyopathy and heart failure via mechanisms including direct myocardial toxicity and endothelial dysfunction.[52][53] However, establishing causality remains contested, as confounders like concurrent tobacco use, high-sodium diets, and sedentary lifestyles prevalent in khat-using populations (e.g., in East Africa and Yemen) may amplify associations; longitudinal data indicate blood pressure normalizes within weeks of cessation in moderate users without underlying pathology, suggesting reversibility absent cumulative damage.[54][55] Neurologically, cathine promotes central nervous system excitation akin to mild amphetamines, frequently causing insomnia and restlessness due to prolonged dopamine and norepinephrine elevation, with self-reported and polysomnographic studies documenting reduced sleep latency and efficiency in habitual khat users chewing 200-500g daily.[56] Anxiety and irritability emerge acutely in susceptible individuals, potentially from noradrenergic overstimulation, though empirical thresholds vary; controlled trials note these subside post-peak plasma levels (reached 1-2 hours after ingestion).[57] Seizures are rare and dose-dependent, documented primarily in overdose scenarios exceeding 100mg pure cathine equivalents, linked to excitotoxic glutamate release, but population-level incidence remains low (<1% in heavy users per regional surveys) without predisposing epilepsy.[38] Chronic exposure may contribute to cerebrovascular risks, including ischemic stroke via vasospasm or hypertension-mediated damage, as evidenced by elevated stroke odds ratios (1.5-2.0) in khat-endemic cohorts, though dietary and metabolic confounders complicate attribution.[38][58]

Other Adverse Effects

Cathine, consumed primarily via khat chewing, is linked to oral health detriments including dental caries, periodontal disease with gingival recession and attachment loss, and keratotic white lesions occurring in 22.4% of chewers versus 0.6% of non-chewers. [3] [19] Studies on khat users have also identified substantial enamel erosion attributable to the mechanical and chemical irritation from prolonged chewing. [59] Gastrointestinal adverse effects include dry mouth, chronic gastritis, and constipation, the latter self-reported by 80.8% of habitual users in a study of college students and 54% in earlier surveys of khat chewers. [60] [40] These effects stem from cathine's sympathomimetic properties, which reduce salivary flow and gastrointestinal motility. [3] Excessive use may precipitate transient psychiatric disturbances such as paranoia with persecutory delusions and irritability, though these are generally milder and self-limiting compared to methamphetamine-induced states. [40] Unlike methamphetamine, cathine lacks a robust association with persistent psychosis, with khat-related episodes typically resolving within 3–11 days of abstinence and linked more to cathinone content or polydrug factors than cathine alone. [40] [3] Cathine demonstrates low acute toxicity, with a rat LD50 of approximately 306 mg/kg—substantially higher than recreational doses of 20–50 mg—resulting in rare direct overdose fatalities. [2] Empirical data from forensic cases indicate khat-involved deaths often involve elevated cathinone levels or comorbidities rather than cathine isolation, underscoring its narrower margin for lethality relative to potent synthetic stimulants. [61]

Dependence, Withdrawal, and Abuse Potential

Addiction Mechanisms

Cathine, the primary psychoactive alkaloid responsible for khat's stimulant effects, promotes dependence through moderate activation of the mesolimbic dopamine pathway, releasing dopamine via inhibition of reuptake and monoamine oxidase-B (MAO-B), though this occurs to a lesser degree than with amphetamines due to cathine's slower onset and lower potency.[62][7] In the nucleus accumbens shell, cathine influences neuronal firing via both D1-like and D2-like dopamine receptors, contributing to reward signaling but with reduced intensity compared to synthetic cathinones or cocaine, as evidenced by animal self-administration studies showing limited reinforcing efficacy.[29][62] Psychological habituation predominates as the core mechanism of dependence, driven by conditioned reinforcement and tolerance rather than robust physical withdrawal, with khat eliciting dose-dependent conditioned place preference in rodent models indicative of rewarding potential but relapse vulnerability upon cue exposure.[7][63] Human and animal data reveal low overall addiction prevalence, with dependence rates of 5-15% among chronic khat users in high-consumption East African populations, underscoring weaker neuroadaptations than those seen in amphetamine dependence.[62][7] Risk factors include concurrent use with tobacco, which amplifies dopaminergic reinforcement through shared nicotinic pathways, and potential genetic vulnerabilities to stimulant habituation, though specific polymorphisms for cathine remain understudied relative to broader substance use disorders.[64][65]

Withdrawal Symptoms and Treatment

Withdrawal from cathine, a primary alkaloid in khat (Catha edulis), typically occurs following cessation of chronic use and is characterized by a range of psychological and physical symptoms that are generally milder than those associated with stronger stimulants like amphetamines or opioids. Common symptoms include depression (reported by 65% of users in one study), intense cravings (44%), fatigue (37%), irritability (27%), increased appetite (30%), hypersomnia (21%), and restlessness or nervousness. Less frequent manifestations encompass poor motivation, negative affect, nightmares (21%), insomnia (14%), mood swings, and mild physical complaints such as headaches or poor coordination. These symptoms reflect the rebound from cathine's stimulant effects on dopamine and norepinephrine systems, leading to dysphoria and motivational deficits upon abrupt discontinuation.[66][67] Symptoms typically emerge within 24-48 hours of cessation, peak between days 2-7 (with some studies noting a maximum around day 7 for depression, craving, and irritability), and largely resolve within 1-2 weeks as the body readapts, underscoring the self-limiting nature of the syndrome. Cravings and psychological symptoms like irritability may persist longer in heavy users but often return toward baseline by the second week. Prevalence of withdrawal experiences is high among dependent users, with approximately 68% of student khat chewers reporting symptoms, though severity correlates with duration and intensity of prior use rather than indicating severe physiological dependence. Unlike opioid withdrawal, cathine cessation does not typically involve life-threatening autonomic hyperactivity, contributing to its relatively benign profile.[67][68][66] No specific pharmacological antagonists exist for cathine withdrawal, as its mechanisms do not lend themselves to targeted reversal agents like those for opioids. Treatment emphasizes supportive care, including hydration, nutrition, and rest to manage fatigue and appetite changes, alongside monitoring for severe depression that might warrant short-term antidepressants in clinical settings. For heavy or dependent users, behavioral interventions such as cognitive-behavioral therapy (CBT) address cravings and relapse triggers, with empirical evidence from abstinence programs showing feasibility despite low unaided quit success rates (e.g., monitored quit attempts revealing persistent symptoms necessitating support). Medically supervised detoxification is recommended for polysubstance users or those with comorbidities, but outpatient management suffices for most due to the mild trajectory; success relies on addressing social and habitual factors, as seen in community-based education and referral models.[69][67][68]

Legal and Regulatory Status

International Controls

Cathine is classified under Schedule III of the United Nations Convention on Psychotropic Substances of 1971, which imposes controls on production, trade, and distribution while allowing limited medical and scientific uses under license.[70] This scheduling reflects its recognition as a stimulant with amphetamine-like effects derived from the khat plant (Catha edulis), though less potent than cathinone, which is in Schedule I of the same convention.[71] The inclusion in Schedule III followed World Health Organization assessments in the early 1980s, emphasizing risks of abuse despite some therapeutic potential as an anorectic.[72] In international sports regulations, cathine has been prohibited by the International Olympic Committee since 1988 within the class of specified stimulants.[73] The World Anti-Doping Agency maintains this ban under its Prohibited List, effective annually including through 2025, with a urinary threshold of 5 micrograms per milliliter to distinguish exogenous use from possible dietary exposure via khat consumption.[74] Exceedance triggers sanctions, as it indicates potential performance enhancement through sympathomimetic effects on alertness and endurance. Cathine is not scheduled under the 1961 Single Convention on Narcotic Drugs, distinguishing it from opioids and cannabis, nor under the 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances for precursor controls.[75] As of 2025, no amendments to its UN scheduling have occurred, though international bodies continue monitoring synthetic cathinone analogs for potential addition to psychotropic schedules due to emerging abuse patterns.[76]

Variations by Country and Recent Changes

Cathine, as a principal active alkaloid in khat (Catha edulis), exhibits significant regulatory variations across jurisdictions, primarily due to differing implementations of the 1971 United Nations Convention on Psychotropic Substances, under which cathine is listed in Schedule III while the khat plant itself remains uncontrolled internationally.[77] In producer nations such as Ethiopia and Yemen, khat consumption and trade are legally permitted and economically vital, supporting cultural practices and exports valued at millions annually, with no specific prohibitions on cathine extraction or use tied to the plant. Conversely, in the United States, khat is classified as a Schedule I substance under the Controlled Substances Act due to its cathinone content (Schedule I) and cathine, rendering possession, importation, or distribution federally illegal since 1993 for cathinone and with cathine controls predating that.[78] Within the European Union, cathine faces controls in most member states, including bans in countries like Germany, France, and Sweden, though enforcement varies; for instance, the United Kingdom reclassified khat as a Class C drug in 2014, prohibiting its sale and possession amid concerns over diaspora markets.[4] Canada similarly prohibits khat importation and use under its Controlled Drugs and Substances Act, aligning with North American patterns of stringent bans.[79] African regulations diverge notably: khat is tolerated and legal in Kenya, where it sustains a multimillion-dollar industry despite cathine and cathinone being designated Class C substances, while Somalia maintains legality for domestic use, though intermittent import restrictions from Kenya have occurred, such as a 2016 ban.[80] These inconsistencies underscore tensions between cultural acceptance in origin countries and prohibitive stances elsewhere, often influenced by migration patterns from khat-using regions like the Horn of Africa. No substantive regulatory shifts for cathine or khat have emerged as of October 2025, though debates persist in the UK and Sweden regarding enforcement efficacy and links to immigrant communities, with reports indicating underground persistence a decade post-UK ban.[81] Such discussions have not prompted reversals or new legislation in 2023–2025.[82]

Effects in Pregnancy and Development

Maternal and Fetal Risks

Khat consumption during pregnancy, which exposes the mother to cathine as a primary sympathomimetic alkaloid, has been linked to maternal physiological disruptions including anemia and premature rupture of membranes.[83][84] Observational studies in khat-endemic regions report lower mean hemoglobin levels among chewing pregnant women, potentially exacerbating maternal hemodynamic stress.[85] These effects stem from cathine's amphetamine-like stimulation of sympathetic activity, promoting vasoconstriction that impairs systemic and uterine perfusion.[86] Maternal risks extend to heightened incidence of preterm labor and induced labor, attributed to cathine-induced uterine irritability and reduced blood flow.[85][87] In a study of Yemeni pregnant women, khat chewers faced elevated odds of labor induction, possibly preterm, due to these vascular mechanisms.[88] Empirical evidence remains observational and region-specific, with no randomized trials isolating cathine's role, though sympathomimetic properties parallel those of other stimulants causing similar obstetric complications.[89] Fetal exposure via placental transfer of cathine contributes to intrauterine growth restriction, manifesting as low birth weight (LBW, <2500 g). Multiple cohort studies quantify this risk: one Ethiopian analysis found khat use associated with adjusted odds ratios of 2.51 for LBW.[90] Another reported an adjusted relative risk of 4.17 among chewers.[91] Frequency-dependent effects are evident, with monthly khat use yielding adjusted odds of 9.5 for LBW infants.[92] Mechanisms involve cathine-mediated vasoconstriction reducing uteroplacental blood flow, limiting nutrient and oxygen delivery, akin to effects observed with other psychostimulants.[89][93] Additional fetal vulnerabilities include distress and intrauterine fetal demise, reported in khat-using pregnancies, likely from chronic hypoxia secondary to placental insufficiency.[85] Animal models of khat alkaloids demonstrate direct placental vasoconstriction, supporting causal inference for growth restriction, though human data derive primarily from khat epidemiology rather than isolated cathine pharmacokinetics in pregnancy.[94] Stillbirth associations appear in some reviews, underscoring the need for abstinence to mitigate these in utero risks.[94]

Empirical Evidence from Studies

Observational cohort and cross-sectional studies from khat-endemic regions such as Ethiopia and Yemen have reported associations between maternal khat chewing during pregnancy and adverse fetal outcomes, including increased risks of stillbirth, low birth weight, and preterm delivery. For instance, a 2021 systematic review and meta-analysis of Ethiopian studies found that khat use was linked to a threefold higher odds of low birth weight infants (pooled OR 3.0, 95% CI 1.9-4.7), based on data from over 5,000 pregnancies across multiple cohorts. Similarly, epidemiological data from Yemen indicated elevated stillbirth rates among khat users, with one study reporting an adjusted odds ratio of 2.5 for perinatal mortality after controlling for some demographic factors. These findings derive primarily from self-reported khat exposure in resource-limited settings where prevalence exceeds 20-30% among pregnant women.[94][95] However, these associations are confounded by socioeconomic factors, poor nutrition, and co-use of tobacco or alcohol, which are prevalent in the same populations and independently linked to poor reproductive outcomes. Studies often rely on retrospective designs with unmeasured variables like gestational timing of exposure or polydrug use, limiting causal inference; for example, a 2023 Ethiopian cohort of 634 women adjusted for parity and education but not fully for dietary inadequacies or poverty, yielding wide confidence intervals (e.g., OR 2.4 for congenital defects, 95% CI 1.1-5.2). Randomized controlled trials are absent due to ethical constraints on exposing pregnant participants to stimulants, leaving evidence at the level of moderate-quality observational data rather than the robust causation demonstrated for tobacco via prospective cohorts and animal models.[96][97] Meta-analyses synthesize these limitations, showing consistent but modest risk elevations (e.g., pooled relative risk 1.5-3.0 for low birth weight across 10+ studies) without establishing dose-response relationships, as khat potency varies by plant freshness and chewing duration, often unquantified in surveys. Cultural patterns of use, involving social rituals that may enhance maternal support or reduce isolation, could mitigate some risks in endemic areas, though no studies isolate this effect. Gaps persist in long-term neurodevelopmental follow-up and isolated cathine exposure, with khat studies conflating alkaloids like cathinone; analogous data on pseudoephedrine (a structural relative) from large cohorts report no malformation increase (adjusted OR 1.0, 95% CI 0.8-1.3), underscoring the need for khat-specific mechanistic research.[90][98]

Controversies and Debates

Cultural and Social Benefits vs. Health Concerns

In traditional East African and Yemeni agrarian societies, khat chewing has been linked to perceived enhancements in work output, with users reporting reduced fatigue and sustained alertness that enable longer labor sessions in farming and herding.[99] Advocates of moderate consumption argue that its stimulant properties, primarily from cathine and cathinone, postpone exhaustion and boost performance without the severe impairment seen in other substances.[100] Empirical observations in regions like Harar, Ethiopia, suggest that habitual users integrate khat into daily routines to maintain productivity, contrasting with claims of universal productivity loss.[101] Socially, khat serves as a facilitator of communal bonding in Yemen and Somalia, where group chewing sessions promote talkativeness, idea-sharing, and social cohesion during rituals, religious gatherings, or political discussions, often positioned as a non-intoxicating alternative to alcohol that avoids disinhibition or aggression.[102] In these contexts, it elevates mood, confidence, and attentiveness without the sedative aftermath of ethanol, fostering extended interpersonal interactions integral to cultural identity.[17] Pro-khat perspectives emphasize its role in economic reliance, as cultivation provides livelihoods for farmers in arid regions, generating revenue that supporters claim outweighs moderated health drawbacks.[103] Health concerns, including elevated heart rate, hypertension, and potential cognitive deficits from chronic heavy use, are documented but often context-dependent, with studies indicating milder effects among habitual users tolerant to its sympathomimetic actions.[104] Moderate traditional consumption shows addiction rates far below those of opioids or cocaine, akin to caffeine dependence, lacking evidence of widespread epidemics in endemic areas where social norms regulate intake.[105] Critics, however, highlight amplified risks in migrant communities, such as Somalis in Western countries or refugee settings, where decontextualized use correlates with higher abuse, PTSD exacerbation, and social isolation due to disrupted cultural controls and stressors like unemployment.[106] [107] In non-native environments, harms may be overstated relative to benefits by overlooking dosage variability, yet empirical data underscore elevated problematic patterns outside regulated social frameworks.[108]

Comparisons to Legal Stimulants and Policy Implications

Cathine, the primary active alkaloid responsible for the sustained stimulant effects of khat after initial cathinone degradation, induces mild central nervous system stimulation comparable to that of caffeine, including increased alertness and reduced fatigue, but with a pharmacological profile closer to ephedrine due to its sympathomimetic properties as norpseudoephedrine.[3][21] Unlike alcohol, which carries significant risks of hepatotoxicity, acute aggression, and high abuse liability leading to widespread societal harms such as traffic fatalities and domestic violence, cathine lacks these depressant effects and associated organ damage, with empirical data indicating lower overall toxicity in chronic users.[109][39] Cathine's abuse potential is substantially reduced relative to amphetamines, manifesting primarily as psychological dependence rather than severe physiological addiction, and it does not precipitate the same escalation to polydrug abuse or overdose mortality seen with stronger stimulants.[109][110] Regulatory asymmetries persist despite these parallels to sanctioned stimulants like caffeine, which is ubiquitous in beverages and energy drinks without equivalent controls, and alcohol, legally available despite documented higher public health burdens including over 3 million annual global deaths.[109] Bans on khat and cathine in countries such as the UK (effective 2014) and the Netherlands (2012) have been critiqued for prioritizing cultural stigma and community pressures over empirical risk assessments, with evidence suggesting influences from xenophobic sentiments toward East African and Yemeni immigrant populations rather than proportionate responses to harm data.[111][112] In producer nations like Ethiopia and Yemen, where khat remains legal and culturally embedded, no surges in organized crime or violence have been empirically linked to its availability, contrasting with post-ban scenarios in Europe where criminalization elevated prices, spurred adulteration with synthetic cathinones, and shifted markets underground without curbing use.[113][111] Policy implications favor evidence-driven regulation over outright prohibition, as controlled markets in origin countries demonstrate feasibility for quality oversight and taxation, potentially mitigating risks like pesticide residues or substitution with more dangerous analogs—outcomes absent in banned jurisdictions where enforcement diverts resources without proportional benefits.[114][111] Debates in producer states, including calls for export licensing and harm reduction education, underscore khat's economic role—contributing up to 20% of GDP in parts of East Africa—while highlighting that bans elsewhere exacerbate smuggling networks without addressing underlying mild stimulant profile akin to legal alternatives.[114][115] Such asymmetries reflect non-empirical drivers, including moral panics, over data indicating cathine's risks are manageable through targeted interventions rather than criminalization.[112]

References

  1. Cathine | C9H13NO | CID 441457 - PubChem - NIH
  2. Cathine: Uses, Interactions, Mechanism of Action | DrugBank Online
  3. Chemistry, Pharmacology, and Toxicology of Khat (Catha Edulis ...
  4. Khat drug profile | www.euda.europa.eu - European Union
  5. L-Norpseudoephedrine - an overview | ScienceDirect Topics
  6. Synthetic Cathinones: Chemical Phylogeny, Physiology, and ...
  7. Khat, a Cultural Chewing Drug: A Toxicokinetic and Toxicodynamic ...
  8. UNODC - Bulletin on Narcotics - 1980 Issue 3 - 002
  9. Thermal Degradation of Synthetic Cathinones - Oxford Academic
  10. Khat: History, Chemistry and Moral Panic | Nature's Poisons
  11. [PDF] Khat and the creation of tradition in the Somali diaspora
  12. Khat - an overview | ScienceDirect Topics
  13. Khat: A widely used drug of abuse in the Horn of Africa and the ...
  14. Khat Uses, Benefits & Dosage - Drugs.com
  15. The Appetite Suppressant D-norpseudoephedrine (Cathine) Acts via ...
  16. [PDF] Khat in the Horn of Africa
  17. Khat use and related addiction, mental health and physical disorders
  18. Prevalence, determinants and impacts of khat chewing among ...
  19. Oral Health Consequences of Khat Use
  20. Cathine - the NIST WebBook
  21. Transcriptome Profiling of Khat (Catha edulis) and Ephedra sinica ...
  22. Developmental patterns of phenylpropylamino alkaloids ...
  23. Proposed biosynthetic routes leading from L-phenylalanine to
  24. Cathinone preservation in khat evidence via drying - ResearchGate
  25. Determination of cathinone and cathine in Khat plant material by LC ...
  26. Pharmacokinetics of cathinone, cathine and norephedrine after the ...
  27. [PDF] SWGDRUG.org - KHAT
  28. Determination of cathinone and cathine in Khat plant material by LC ...
  29. The Appetite Suppressant D-norpseudoephedrine (Cathine) Acts via ...
  30. What is Cathine hydrochloride used for? - Patsnap Synapse
  31. Multifaceted Applications of Synthetic Cathinones and Catha edulis ...
  32. Pharmacokinetics of cathinone, cathine and norephedrine ... - PubMed
  33. Excretion of the Active Principle of Catha edulis (Miraa) in Human ...
  34. Efficacy and Safety of Cathine (Nor-Pseudoephedrine) in the ...
  35. Discriminative stimulus properties of (+)cathine, an alkaloid of the ...
  36. Dopaminergic nature of acute cathine tolerance - ScienceDirect.com
  37. Long-Term Effects of Chronic Khat Use: Impaired Inhibitory Control
  38. Risks of khat chewing on the cardiovascular, nervous ... - NIH
  39. Khat - Alcohol and Drug Foundation
  40. Adverse effects of khat: a review | Advances in Psychiatric Treatment
  41. Efficacy and Safety of Cathine (Nor-Pseudoephedrine) in ... - PubMed
  42. [PDF] Drug Fact Sheet: Khat - DEA.gov
  43. Khat Is Abused All Over the World, and It's Coming to America
  44. Prevalence of Khat (Catha edulis) Chewing and Its Determinants
  45. Khat use in Europe | Transnational Institute
  46. A Pilot Study on Khat Consumption Among Yemeni Migrants in ...
  47. (PDF) Khat use in Europe: implications for European policy
  48. The Prohibited List | World Anti Doping Agency - WADA
  49. Khat Chewing and Cardiovascular Disease - PMC - PubMed Central
  50. Khat Chewing Induce Transient Elevation of Blood Pressure
  51. Khat (Catha Edulis) as a Risk Factor for Cardiovascular Disorders
  52. Association of Chronic Khat Chewing with Blood Pressure and ...
  53. Understanding the Intricacies of Khat-Associated Cardiovascular ...
  54. Khat chewing and cardiovascular risk profile in a cohort of Yemeni ...
  55. Regular Khat (Catha edulis) chewing is associated with elevated ...
  56. Khat Use and Neurobehavioral Functions: Suggestions for Future ...
  57. Khat and neurobehavioral functions: A systematic review | PLOS One
  58. Risks of khat chewing on the cardiovascular, nervous,... - LWW
  59. The Effects of Khat Chewing among Djiboutians: Dental Chemical ...
  60. Prevalence, Reasons, and Perceived Effects of Khat Chewing Among
  61. Fatalities Involving Khat in Jazan, Saudi Arabia, 2018 to 2021 - NIH
  62. [PDF] Khat: Assessment of Risk to the Individual and Society in the UK
  63. Khat-induced conditioned place preference, extinction, and ...
  64. Exploring the perception of key stakeholders toward khat policy ...
  65. Do the risks of khat-induced dependence and psychosis warrant the ...
  66. Prevalence, withdrawal symptoms and associated factors of khat ...
  67. Khat withdrawal symptoms among chronic khat users following a ...
  68. Khat Withdrawal: Symptoms, Timeline & Treatment | Gratitude Lodge
  69. Khat Treatment and Withdrawal
  70. International Drug Scheduling; Convention on Psychotropic ...
  71. [PDF] CONVENTION ON PSYCHOTROPIC SUBSTANCES, 1971
  72. (PDF) Scheduling synthetic cathinone substances under the ...
  73. Pharmacology of stimulants prohibited by the World Anti-Doping ...
  74. [PDF] International Standard for Prohibited List - WADA
  75. [PDF] List of Psychotropic Substances under International Control - INCB
  76. Prohibited List | World Anti Doping Agency - WADA
  77. Details for Plant-based substances - unodc
  78. Khat Fast Facts - Department of Justice
  79. Uncovering the Truth About Khat Drug | Canadian Centre for ...
  80. Khat in Kenya: why efforts to ban this popular stimulant are unlikely ...
  81. Banned and 'forgotten' drug: What happened to khat? - BBC
  82. Synthetic cathinones: an updated harms assessment (accessible)
  83. Khat use and related determinants among pregnant women within ...
  84. Magnitude and risk factors of khat, alcohol and cigarettes use ...
  85. Khat chewing in pregnant women associated with prelabor rupture ...
  86. Coronary and aortic vasoconstriction by cathinone, the active ...
  87. Caffeine consumption, khat chewing, and associated factors among ...
  88. Khat Chewing During Pregnancy: an Insight on an Ancient Problem ...
  89. Placental Complications Associated With Psychostimulant Use in ...
  90. The effects of khat use during pregnancy on perinatal and maternal ...
  91. The impact of chewing khat during pregnancy on selected ...
  92. Association between maternal khat use and other determinants and ...
  93. Stimulant Use in Pregnancy – an under-recognized epidemic ...
  94. The effect of substance use during pregnancy on neonatal outcomes ...
  95. The effect of substance use during pregnancy on neonatal outcomes ...
  96. The effect of possible mediators on the association between ...
  97. The effect of substance use during pregnancy on neonatal outcomes ...
  98. Exposure to pseudoephedrine during pregnancy and major ...
  99. An assessment of khat consumption habit and its linkage to ...
  100. [PDF] the chewing of khat (catha edulis ) in the horn of africa and arabian ...
  101. [PDF] Socio-Economic Impact of Khat in Mana District, Jimma Zone, South ...
  102. Understanding Khat: Its Sociocultural and Health Implications in ...
  103. [PDF] Khat (Catha edulis): the herb with officio-legal, socio-cultural and ...
  104. Khat (Catha edulis): A systematic review of evidence and literature ...
  105. What constitutes problematic khat use? An exploratory mixed ...
  106. Khat Use, PTSD and Psychotic Symptoms among Somali Refugees ...
  107. Reducing Khat use among Somalis living in Kenya: a controlled pilot ...
  108. habitual khat chewing: Topics by Science.gov
  109. Abuse Potential of Cathinones in Humans: A Systematic Review
  110. https://www.caymanchem.com/news/stimulant-use-and-abuse
  111. [PDF] Chewing over Khat prohibition - Transnational Institute
  112. [PDF] The UK khat ban: Likely adverse consequences | Swansea University
  113. Consequences of criminalisation: the Dutch khat market before and ...
  114. dilemmas and opportunities for the international drug control system
  115. Legislative Reform Series - Chewing over Khat prohibition
User Avatar
No comments yet.